Carboplatin and Pemetrexed Chemotherapy Regimen

What Is Carboplatin + Pemetrexed?

The combination of carboplatin and pemetrexed is a non-small-cell lung cancer (NSCLC) treatment and a widely used lung cancer chemotherapy regimen. These medicines disrupt cancer cells by targeting their DNA , preventing division and causing cell death.

Treatment Goals

• Localized Lung Cancer: If the disease is confined to the lung and has not spread elsewhere, the aim is complete recovery (cure).

• Metastatic Lung Cancer: If the cancer has spread to other parts of the body, the aim is to shrink the tumor and relieve disease-related symptoms.

• Stage 3 NSCLC Unsuitable for Surgical Removal: Durvalumab (Imfinzi) immunotherapy may be used in selected patients after carboplatin + pemetrexed and radiotherapy to slow progression and extend survival.

What Is Carboplatin?

Carboplatin, a platinum-based alkylating agent , is a chemotherapy medicine that directly damages DNA and prevents cancer cell division.

Mechanism of Action:

• Carboplatin forms cross-links at guanine bases in cancer cell DNA (within DNA strands and between strands).
• These cross-links prevent proper DNA replication and repair.
• Damaged DNA halts the cell cycle and triggers apoptosis (programmed cell death).
• Healthy cells may also be affected, but because cancer cells divide faster, carboplatin primarily targets them.

Pharmacological Properties:

• Target: Rapidly dividing cells, particularly cancer cells replicating DNA.
• Administration: Intravenous (IV) infusion.
• Renal elimination: Dose adjustment must be based on kidney function.
• Most common adverse effects: Myelosuppression, particularly thrombocytopenia; nausea/vomiting; kidney damage; neurotoxicity.

Advantage: Compared with cisplatin, it carries lower risks of kidney damage and neurotoxicity, although kidney function still requires careful monitoring.

What Is Pemetrexed?

Pemetrexed, an antimetabolite chemotherapy agent , is a folate analog that inhibits enzymes needed for DNA synthesis, stopping cancer cell growth.

Mechanism of Action:

• Pemetrexed inhibits three main folate-dependent enzymes:

  1. Thymidylate synthase (TS): Inhibits production of thymidylate needed for DNA synthesis, preventing DNA replication.
  2. Dihydrofolate reductase (DHFR): Disrupts the folate cycle and disables cellular repair mechanisms.
  3. Glycoinosine monophosphate transformylase (GARFT): Inhibits purine synthesis, thereby also stopping RNA synthesis and limiting cell growth.

• Through these three effects, pemetrexed stops rapidly dividing cancer cells from growing and triggers apoptosis (cell death).

• It is particularly effective in folate-dependent cancers such as adenocarcinoma-type NSCLC and malignant mesothelioma.

Pharmacological Properties:

• Target: Rapidly dividing cells synthesizing DNA and RNA.
• Administration: Intravenous (IV) infusion.
• Renal elimination: Doses must be adjusted in patients with kidney failure.
• Supportive treatment: Folic acid and vitamin B12 supplementation before and during treatment is mandatory to prevent adverse effects.
• Most common adverse effects: Myelosuppression (leukopenia, anemia, thrombocytopenia), mucositis, nausea/vomiting, fatigue, and skin rash.

Advantage: Folic acid and vitamin B12 supplements can reduce adverse effects.

Treatment Schedule

Carboplatin/Pemetrexed Administration Schedule

• Carboplatin: On day 1, a 30-minute intravenous (IV) infusion is administered.

• Pemetrexed: On day 1, a 10-minute IV infusion is administered.

• Total infusion time:

  • Approximately 2 hours on day 1 may be needed.

  • Additional premedication and hydration may take extra time.

This regimen is usually given in outpatient treatment centers without hospital admission. It may also be given in hospital to patients requiring admission.

• Treatment cycle: Repeated every 21 days (1 cycle).

• Nonmetastatic patients may receive up to 6 cycles .

• When combined with radiotherapy, 4 cycles may be given.

• Metastatic patients continue treatment until disease progression or intolerable adverse effects.

Adverse Effects

Each medicine has different adverse effects. With combined use, the most frequently reported effects are:

• Low white blood cell count (leukopenia) - 63%

• Nausea and vomiting - 57%

• Low platelet count (thrombocytopenia) - 51%

• Fatigue - 44%

• Liver damage - 22%

• Low red blood cell count (anemia) - 21%

• Hair loss - 16%

• Skin rash - 7%

• Bowel problems (constipation / diarrhea) - 7-12%

• Febrile neutropenia - 3-5%

• Kidney damage - 10%

Adverse effects may force 1-13% of patients to stop treatment early.

Monitoring and Observation

• Blood tests: Before treatment and at regular intervals, a complete blood count and biochemical tests  should be performed.

• Imaging: Before, during, and after treatment, X-ray, CT, PET, or MRI  may be performed.

Based on results, the doctor may decide to:

• Continue at the same dose,

• Reduce the dose,

• Pause treatment,

• Switch to an alternative treatment.

Precautions During Treatment

• NSAID Use: Avoid NSAIDs such as ibuprofen and naproxen for 2-5 days before pemetrexed and at least 2 days afterward.

• Vitamin Supplements:

  • Vitamin B12 (Dodex®) injections should begin 3-5 days before treatment and be given every 9 weeks (every 3 cycles).

  • Folic acid (Folbiol®) should start 7 days before pemetrexed and continue for 21 days after treatment ends.

• Dexamethasone Use: To prevent skin reactions, oral Kordexa 8 mg tablets may be taken twice daily on the night before pemetrexed and the morning of chemotherapy.

• Carboplatin Allergic Reactions: Serious reactions may occur particularly after 6-9 cycles, so desensitization protocols may be used.

Consult your doctor during treatment to learn about possible adverse effects and alternatives.